In another phase 3 study performed on patients with chronic lymphocytic leukemia (CLL), the disruption of the tumor suppressor pathway TP53 by downregulation of the 34° microRNA with deletion of 17p13 (del17p) to complete loss of TP53 function was associated with a poor prognosis [50]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.